Leqvio (inclisiran) may cause injection site reactions, including bruising, pain, discoloration, itchiness, and a burning or prickling sensation at the injection site. In addition to injection site ...
Scientists in South Korea have used artificial intelligence (AI) and supercomputers to design a powerful new ...
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
Peptinov today announced the publication of the Phase 1 clinical results for PPV-06, its first-in-class active immunotherapy targeting IL-6, in the peer-reviewed journal Nature Communications. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback